TL;DR
While Eli Lilly maintains its overall dominance in the obesity market with injectable tirzepatide, Novo Nordisk has firmly captured the oral market with a massive lead for oral Wegovy over Lilly's Foundayo. Meanwhile, the long-term competitive horizon is shifting rapidly as generic challengers target Lilly's core patents, and clinical-stage rivals like Viking Therapeutics diversify into alternative mechanisms like amylin.
Novo Nordisk Establishes Dominance in the Oral Weight-Loss Segment
Novo Nordisk is translating its first-mover advantage and household brand recognition into near-total control of the newly formed oral GLP-1 market, leaving Eli Lilly's rival pill struggling for traction.
"According to IQVIA prescription data compiled for the week ending July 17, 2026, oral Wegovy is maintaining a high-volume trajectory... capturing 89% of the oral weight-loss pill prescription volume and successfully fending off Eli Lilly's rival pill, Foundayo..." — [novo-nordisk-q1-2026-oral-wegovy-cagrisema
]
This dominance is reinforced by structural advantages, as detailed by the Wall Street Journal, including Novo's immediate day-one formulary coverage and superior clinical trial efficacy of 16.6% weight loss compared to Foundayo's 12.4% novo-nordisk-q1-2026-oral-wegovy-cagrisema. For Lilly, reversing this trend will require overcoming delayed insurance coverage and the steep challenge of building a new consumer brand from scratch lilly-q1-2026-earnings-foundayo-launch
.
What to watch: Watch Novo Nordisk's upcoming Q2 earnings call on August 5, 2026, where analysts will heavily scrutinize oral Wegovy's long-term patient retention rates novo-nordisk-q1-2026-oral-wegovy-cagrisema.
Generic Challengers Move to Crack the Tirzepatide Monopoly
The long-term financial moat protecting the industry's most lucrative injectables is facing its first major structural challenge as global generic giants coordinate regulatory filings to break Eli Lilly's patents.
"Sandoz is building its GLP-1 development platform and this submission reflects true in-house innovation. It represents a key first step in our efforts to bring this medicine to market and underscores our ambition to increase competition and expand affordability..." — [lilly-q1-2026-earnings-foundayo-launch
]
By filing Abbreviated New Drug Applications with Paragraph IV patent challenges, generic manufacturers like Sandoz and Hybio Pharmaceutical are forcing Lilly into defensive litigation lilly-q1-2026-earnings-foundayo-launch. While Lilly's patents are technically valid until 2036, these aggressive legal maneuvers threaten to significantly accelerate the timeline for low-cost alternatives lilly-q1-2026-earnings-foundayo-launch
.
What to watch: Watch for Eli Lilly to initiate patent infringement lawsuits against Sandoz and Hybio, which will trigger an automatic 30-month FDA approval stay on generic tirzepatide lilly-q1-2026-earnings-foundayo-launch.
Clinical-Stage Contenders Diversify to Avoid the GLP-1 Bottleneck
Mid-tier biotechnology companies are rapidly expanding into alternative metabolic pathways like amylin to create differentiated combination therapies and bypass the crowded GLP-1 landscape.
"Therapies that target amylin and calcitonin receptors may potentially be used alone or in combination with GLP-1 or dual GLP-1/GIP agonists to improve the induction of weight loss as well as for longer-term weight management." — [viking-therapeutics-vktx-ma-target-oral-vk2735-2026
]
Viking Therapeutics' initiation of a Phase 1 trial for its amylin agonist VK3019 represents a strategic hedge viking-therapeutics-vktx-ma-target-oral-vk2735-2026. By developing a second metabolic pathway alongside its core dual GLP-1/GIP agonist VK2735, the company aims to offer flexible weight-loss induction and maintenance options that stand out from existing monotherapies viking-therapeutics-vktx-ma-target-oral-vk2735-2026
.
What to watch: Watch for Viking to report results from its Phase 1 study exploring various VK2735 maintenance dosing regimens in the third quarter of 2026 viking-therapeutics-vktx-ma-target-oral-vk2735-2026.
What surprised us
- Novo's absolute crushing of Lilly in the oral market. While Lilly maintains a dominant 59.5% share of the overall U.S. obesity market through injectables, Novo's oral Wegovy has completely monopolized the oral segment, commanding an 89% market share lilly-q1-2026-earnings-foundayo-launch
- The speed of the generic onslaught. Sandoz and Hybio filing abbreviated applications for tirzepatide generic alternatives so early in the drug's commercial life shows that generic manufacturers are moving at unprecedented speed to target the GLP-1 gold rush lilly-q1-2026-earnings-foundayo-launch
- Viking's aggressive dual-track oral strategy. Beyond its subcutaneous trials, Viking is planning to initiate a Phase 3 trial for its oral tablet formulation of VK2735 in late 2026, positioning itself to potentially deliver the first oral dual GLP-1/GIP agonist on the market viking-therapeutics-vktx-ma-target-oral-vk2735-2026